Graham E. Trope

Mid-term Effects of Neodymium:YAG Transscleral Cyclocoagulation in Glaucoma

Neodymium: YAG (Nd:YAG) transscleral cyclocoagulation successfully lowers intraocular pressure (IOP) over the short term in animals and humans. Twenty-eight eyes with uncontrolled glaucoma were prospectively followed over a mean period of 21.9 months. Mean pretreatment IOP was 47.5 mmHg. Mean posttreatment IOP was 19.9 mmHg (P less than 0.005). Mean (+/- standard deviation) number of treatments was 1.86 (+/- 1.11) Mean number of drugs used before and after treatment was 3.28 and 2.48, respectively (P less than 0.01). A total of 10.7% eyes went phthisical. Thirty percent of eyes with vision and good IOP control (i.e., less than 21 mmHg) lost some vision after the procedure. Neodymium:YAG transscleral cyclocoagulation appears to be an effective method of controlling IOP over the mid-term, but is associated with significant complications.

Cost of glaucoma in Canada: analyses based on visual field and physician's assessment.

PurposeA longitudinal, retrospective study investigated the cost of primary open angle glaucoma (POAG). MethodsPatient files from two tertiary care glaucoma practices were reviewed. Patients diagnosed with POAG and ≥2.5 years of follow-up data were included. Data collected included visual field mean deviation, physicians assessment, and resource utilization (physician visits, procedures, and medications). Costs, reported in 2001 Canadian dollars, were compared between groups, based on initial visual field mean deviation, including mild (<5 dB), moderate (5 to <12 dB), and severe (≥12 dB), and based on physicians assessment, including controlled, uncontrolled, or patients initially uncontrolled for 12 months who become controlled. ResultsOf 411 patient charts extracted, 265 were included; 35 were excluded for ocular comorbidities and 111 patients with insufficient follow-up. Mean (standard deviation) yearly costs overall (N = 265) and for mild (n = 90), moderate (n = 91), and severe (n = 84) groups were

Laser trabeculoplasty trends with the introduction of new medical treatments and selective laser trabeculoplasty.

508 (

Neodymium:YAG Transscleral Cyclocoagulation in Human Eyes

278),

Neodymium-YAG transscleral cyclocoagulation in rabbit eyes

408 (

Short-term effects of neodymium-YAG transscleral cyclocoagulation in patients with uncontrolled glaucoma.

266),

Survey of complementary and alternative medicine use in glaucoma patients.

512 (

Diurnal intraocular Pressure in Young Adults with Central Retinal Vein Occlusion

288), and

Is the Ex-PRESS glaucoma shunt magnetic resonance imaging safe?

609 (

Conjunctival Complications Related to Ahmed Glaucoma Valve Insertion

243), respectively. Differences between mean yearly costs were statistically significant for all three groups (P < 0.05). Costs for controlled (n = 110), uncontrolled (n = 76), and uncontrolled then controlled group (n = 79) were